• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Bicara Therapeutics Inc.

    9/26/24 4:16:04 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCAX alert in real time by email
    SC 13G 1 tm2424677d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Bicara Therapeutics, Inc.

    (Name of Issuer)

     

    Common stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    055477103

    (CUSIP Number)

     

    September 16, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   055477103
    1. Names of Reporting Persons
    Red Tree Venture Fund, L.P.
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ¨
        (b) x (1)
    3. SEC Use Only
    4. Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
    6. Shared Voting Power
    3,170,509 (2)
    7. Sole Dispositive Power
    0
    8. Shared Dispositive Power
    3,170,509 (2)
    9. Aggregate Amount Beneficially Owned by Each Reporting Person
    3,170,509 (2)
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11. Percent of Class Represented by Amount in Row (9)
    5.8% (3)
    12. Type of Reporting Person (See Instructions)
    PN
           

    (1)This Schedule 13G is filed by Red Tree Venture Fund, L.P. (“Red Tree LP”), Red Tree GP, LLC (Red Tree GP”) and Heath Lukatch (“Lukatch” and, with Red Tree LP and Red Tree GP, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Consists of 3,170,509 shares of Common Stock held by Red Tree LP. Red Tree GP serves as the sole general partner of Red Tree LP and shares voting and dispositive power over the shares owned by Red Tree LP. Lukatch is the Managing Director of Red Tree GP and shares voting and dispositive power over the shares held by Red Tree LP.

     

    (3)This percentage is calculated based upon 54,385,925 shares of Common Stock outstanding as of September 16, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the Securities and Exchange Commission (the “SEC”) on September 13, 2024.

     

     2 

     

     

    CUSIP No.   055477103
    1. Names of Reporting Persons
    Red Tree GP, LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ¨
        (b) x (1)
    3. SEC Use Only
    4. Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
    6. Shared Voting Power
    3,170,509 (2)
    7. Sole Dispositive Power
    0
    8. Shared Dispositive Power
    3,170,509 (2)
    9. Aggregate Amount Beneficially Owned by Each Reporting Person
    3,170,509 (2)
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11. Percent of Class Represented by Amount in Row (9)
    5.8% (3)
    12. Type of Reporting Person (See Instructions)
    OO
           

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Consists of 3,170,509 shares of Common Stock held by Red Tree LP. Red Tree GP serves as the sole general partner of Red Tree LP and shares voting and dispositive power over the shares owned by Red Tree LP. Lukatch is the Managing Director of Red Tree GP and shares voting and dispositive power over the shares held by Red Tree LP.

     

    (3)This percentage is calculated based upon 54,385,925 shares of Common Stock outstanding as of September 16, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on September 13, 2024.

     

     3 

     

     

    CUSIP No.   055477103
    1. Names of Reporting Persons
    Heath Lukatch
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ¨
        (b) x (1)
    3. SEC Use Only
    4. Citizenship or Place of Organization
    United States
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
    6. Shared Voting Power
    3,170,509 (2)
    7. Sole Dispositive Power
    0
    8. Shared Dispositive Power
    3,170,509 (2)
    9. Aggregate Amount Beneficially Owned by Each Reporting Person
    3,170,509 (2)
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11. Percent of Class Represented by Amount in Row (9)
    5.8% (3)
    12. Type of Reporting Person (See Instructions)
    IN
           

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)Consists of 3,170,509 shares of Common Stock held by Red Tree LP. Red Tree GP serves as the sole general partner of Red Tree LP and shares voting and dispositive power over the shares owned by Red Tree LP. Lukatch is the Managing Director of Red Tree GP and shares voting and dispositive power over the shares held by Red Tree LP.

     

    (3)This percentage is calculated based upon 54,385,925 shares of Common Stock outstanding as of September 16, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on September 13, 2024.

     

     4 

     

     

    Item 1.
      (a) Name of Issuer
    Bicara Therapeutics, Inc.
      (b) Address of Issuer’s Principal Executive Offices
    116 Huntington Avenue, Suite 703, Boston, MA 02116
     
    Item 2.
      (a) Name of Person Filing
    Red Tree Venture Fund, L.P. (“Red Tree LP”)
    Red Tree GP, LLC (Red Tree GP”)
    Heath Lukatch (“Lukatch”)
      (b) Address of Principal Business Office or, if none, Residence
    2055 Woodside Road, Suite 270, Redwood City, CA 94061.
      (c) Citizenship      
        Entities: Red Tree LP - Delaware
        Entities: Red Tree GP - Delaware
        Individuals: Lukatch - United States
      (d) Title of Class of Securities
    Common Stock, $0.0001 par value (“Common Stock”)
      (e) CUSIP Number
    055477103
     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      Not applicable
       

    Item 4. Ownership
    The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of September 26, 2024:

     

    Reporting
    Persons
      Shares Held
    Directly
       Sole
    Voting
    Power
       Shared
    Voting
    Power
       Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power
       Beneficial
    Ownership
       Percentage
    of Class (2)
     
    Red Tree LP (1)   3,170,509    0    3,170,509    0    3,170,509    3,170,509    5.8%
    Red Tree GP (1)   0    0    3,170,509    0    3,170,509    3,170,509    5.8%
    Lukatch (1)   0    0    3,170,509    0    3,170,509    3,170,509    5.8%

     

    (1)Consists of 3,170,509 shares of Common Stock held by Red Tree LP. Red Tree GP serves as the sole general partner of Red Tree LP and shares voting and dispositive power over the shares owned by Red Tree LP. Lukatch is the Managing Director of Red Tree GP and shares voting and dispositive power over the shares held by Red Tree LP.
    (2)This percentage is calculated based upon 54,385,925 shares of Common Stock outstanding as of September 16, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on September 13, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following    ¨

     

     5 

     

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
      Not applicable
     
    Item 9. Notice of Dissolution of Group
      Not applicable
     
    Item 10. Certification
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     6 

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: of September 26, 2024  
         
    Red Tree Venture Fund, L.P.  
         
    By: Red Tree GP, LLC  
    its General Partner  
         
    By: /s/ Heath Lukatch  
      Name: Heath Lukatch  
      Title: Managing Director  
         
    Red Tree GP, LLC  
         
    By: /s/ Heath Lukatch  
      Name: Heath Lukatch  
      Title: Managing Director  
         
    /s/ Heath Lukatch  
    Heath Lukatch  

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     7 

     

     

    Exhibit(s):

     

    AJoint Filing Agreement

     

     8 

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Bicara Therapeutics, Inc. is filed on behalf of each of us.

     

    Dated: of September 26, 2024  
         
    Red Tree Venture Fund, L.P.  
         
    By: Red Tree GP, LLC  
    its General Partner  
         
    By: /s/ Heath Lukatch  
      Name: Heath Lukatch  
      Title: Managing Director  
         
    Red Tree GP, LLC  
         
    By: /s/ Heath Lukatch  
      Name: Heath Lukatch  
      Title: Managing Director  
         
    /s/ Heath Lukatch  
    Heath Lukatch  

     

     

    Get the next $BCAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCAX

    DatePrice TargetRatingAnalyst
    4/17/2025$8.00Underweight
    Wells Fargo
    2/6/2025$31.00Outperform
    Wedbush
    12/6/2024$42.00Buy
    H.C. Wainwright
    11/5/2024$48.00Buy
    Rodman & Renshaw
    10/8/2024Overweight
    Cantor Fitzgerald
    10/8/2024$35.00Overweight
    Morgan Stanley
    10/8/2024Buy
    TD Cowen
    10/8/2024$47.00Buy
    Stifel
    More analyst ratings

    $BCAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Possible Members of 10% Group Flynn James E converted options into 1,725,174 shares and bought $1,260,000 worth of shares (70,000 units at $18.00) (SEC Form 4)

      4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

      9/17/24 6:16:55 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Strong financial position with approximately $462 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the first quarter ended March 31, 2025 and provided a business

      5/13/25 7:30:04 AM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

      BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced multiple presentations related to ficerafusp alfa at the American Association for Cancer Research (AACR) Annual Meeting 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types. "We are excited to present s

      4/28/25 4:01:27 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

      BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from the company's ongoing Phase 1/1b clinical trial of ficerafusp alfa in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30-June 3, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets:

      4/23/25 10:00:02 AM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCAX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Bicara Therapeutics Inc.

      10-Q - Bicara Therapeutics Inc. (0002023658) (Filer)

      5/13/25 4:12:04 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bicara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bicara Therapeutics Inc. (0002023658) (Filer)

      5/13/25 7:43:04 AM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.

      SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)

      5/12/25 10:28:12 AM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bicara Therapeutics Inc.

      SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

      9/26/24 4:30:56 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Bicara Therapeutics Inc.

      SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

      9/26/24 4:16:04 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Bicara Therapeutics Inc.

      SC 13D - Bicara Therapeutics Inc. (0002023658) (Subject)

      9/23/24 4:17:42 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Bicara Therapeutics with a new price target

      Wells Fargo initiated coverage of Bicara Therapeutics with a rating of Underweight and set a new price target of $8.00

      4/17/25 8:32:06 AM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Bicara Therapeutics with a new price target

      Wedbush initiated coverage of Bicara Therapeutics with a rating of Outperform and set a new price target of $31.00

      2/6/25 7:05:01 AM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Bicara Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $42.00

      12/6/24 8:08:14 AM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Meisner Lara sold $1,021,211 worth of shares (79,146 units at $12.90) and exercised 79,146 shares at a strike of $5.45 (SEC Form 4)

      4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

      3/18/25 6:35:25 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Possible Members of 10% Group Flynn James E converted options into 1,725,174 shares and bought $1,260,000 worth of shares (70,000 units at $18.00) (SEC Form 4)

      4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

      9/17/24 6:16:55 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ra Capital Management, L.P.

      4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

      9/16/24 5:49:53 PM ET
      $BCAX
      Biotechnology: Pharmaceutical Preparations
      Health Care